Skip to main
BWAY

Brainsway (BWAY) Stock Forecast & Price Target

Brainsway (BWAY) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BrainsWay is an emerging leader in non-invasive neurostimulation treatments, with a strong financial outlook and potential for international growth. Despite potential risks from competition and market slowdown, the company has a proven track record of success with multiple FDA clearances and a growing presence in the market. The recent FDA clearance for their SWIFT accelerated protocol is expected to drive further growth and increase access to treatment, solidifying their position as a top player in the industry.

Bears say

BrainsWay is a medical device company that has demonstrated the ability to scale a TMS business into sustainable profitability through a high-margin, recurring revenue platform, but its future may be at risk with the potential entry of COMP360 psilocybin therapy and competitors in the neurostimulation market, a low market penetration rate for its products, and the uncertainty of international expansion and Deep TMS 360 success. Despite a strong foundation and positive financials, the potential for disruption and increased competition in the near future warrants a negative outlook on the stock.

Brainsway (BWAY) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Brainsway (BWAY) Forecast

Analysts have given Brainsway (BWAY) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Brainsway (BWAY) has a Strong Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Brainsway (BWAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.